Cannabis Use Characteristics and Reasons for Product Choices Among Patients Accessing Treatment for Substance Use Disorders: A Mixed-Methods Study

Authors

  • Justin Matheson Institute for Mental Health Policy Research, Centre for Addiction and Mental Health
  • Harseerat Saini Institute for Mental Health Policy Research, Centre for Addiction and Mental Health; Human Biology Program, Faculty of Arts and Sciences, University of Toronto
  • Rebecca Haines-Saah Cumming School of Medicine, University of Calgary
  • Marcos Sanches Biostatistics Core, Centre for Addiction and Mental Health
  • Matthew E. Sloan Institute for Mental Health Policy Research, Centre for Addiction and Mental Health; Addictions Division, Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto; Department of Pharmacology & Toxicology, University of Toronto; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Department of Psychological Clinical Science, University of Toronto Scarborough; Institute of Medical Science, University of Toronto
  • Adam Zaweel Institute for Mental Health Policy Research, Centre for Addiction and Mental Health; Department of Pharmacology & Toxicology, University of Toronto
  • Ahmed Hassan Institute for Mental Health Policy Research, Centre for Addiction and Mental Health; Addictions Division, Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto; Department of Pharmacology & Toxicology, University of Toronto; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Institute of Medical Science, University of Toronto; Department of Psychiatry, King AbdulAziz University
  • Leslie Buckley Addictions Division, Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto
  • Amy Porath Knowledge Institute on Child and Youth Mental Health and Addictions; Children’s Hospital of Eastern Ontario Research Institute
  • James MacKillop Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University and St Joseph’s Healthcare Hamilton; Peter Boris Centre for Addictions Research, McMaster University and St Joseph’s Healthcare Hamilton; Department of Psychiatry and Behavioural Neurosciences, McMaster University
  • Christian S. Hendershot Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California
  • Stefan Kloiber Department of Psychiatry, University of Toronto; Department of Pharmacology & Toxicology, University of Toronto; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
  • Bernard Le Foll Institute for Mental Health Policy Research, Centre for Addiction and Mental Health; Addictions Division, Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto; Department of Pharmacology & Toxicology, University of Toronto; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Waypoint Research Institute, Waypoint Centre for Mental Health Care

Abstract

Objective: The diversity and potency of cannabis products have increased in recent years, underscoring the importance of understanding which products are being used and why. Patients with substance use disorders (SUDs) use have a high prevalence of risky cannabis use, making it especially important to understand use patterns in this group. We aimed to first describe cannabis product characteristics and then explore reasons for choosing products in our sample.  Method: In this mixed-methods study, 472 adults who self-reported accessing SUD treatment and lifetime cannabis use completed an online survey. A subset of 22 participants completed in-depth interviews. Quantitative results focused on describing cannabis use characteristics (e.g., product types) among participants reporting past-year cannabis use (current use group) or lifetime cannabis use but no use in past year (past use group), while qualitative descriptive analysis was used to describe reasons for choosing products among participants who were currently using cannabis. Results:  Across medical and non-medical use of cannabis, dried flower and smoked cannabis formulations were most used (e.g., 89% of the current use group reported smoking cannabis for non-medical purposes), followed by edibles (e.g., 53% of the current use group used edible formulations of cannabis for non-medical purposes), though there was considerable use of higher-potency products such as concentrates and dabs (e.g., 11% of the current use group had used dabs for non-medical purposes). Our qualitative analysis found that almost all participants were motivated by THC content when purchasing products, yet sometimes perceived medical benefits or harm reduction were reasons for using certain products (especially CBD-dominant products), while sometimes other factors (e.g., convenience, familiarity) were influential. Conclusions: Cannabis use characteristics (including motives for choosing products) are complex and nuanced in patients accessing SUD treatment. More work is needed to understand longitudinal relationships between use of different cannabis products and both harms and potential benefits.

Downloads

Additional Files

Published

2025-07-14

Issue

Section

Original Report